ALISertib in combination with endocrine therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) recurrent or metastatic breast cancer: The phase 2 ALISCA-Breast1 study.

被引：0

作者：

Advani, Pooja Prem

Braga, Sofia A. D. S.

Brufsky, Adam

Giridhar, Karthik

Mayer, Erica L.

McCann, Kelly Elizabeth

O'Regan, Ruth

Saura Manich, Cristina

Wander, Seth Andrew

Bischof, Georg Friedrich

Lowenthal, Beth Hillary

Bebchuk, Judith D.

Eli, Lisa DeFazio

Barnett, Brian

O'Shaughnessy, Joyce

Haddad, Tufia C.

机构：

[1] Mayo Clin, Jacksonville, FL USA

[2] CUF Descobertas, Lisbon, Portugal

[3] Univ Pittsburgh, Pittsburgh, PA USA

[4] Mayo Clin, Rochester, MN USA

[5] Harvard Med Sch, Dana Farber Canc Inst, Med Oncol, Boston, MA USA

[6] Univ Calif Los Angeles, Los Angeles, CA USA

[7] Univ Rochester, Rochester, NY USA

[8] Vall dHebron Univ Hosp, Barcelona, Spain

[9] Massachusetts Gen Hosp, Boston, MA USA

[10] Puma Biotechnol Inc, Los Angeles, CA USA

[11] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA

来源：

关键词：

D O I：

10.1200/JCO.2025.43.16_suppl.TPS1125

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：TPS1125 / TPS1125

页数：1